SLC45A3 and prostate cancer: Similar to ALK fusions, FGFR fusions have been reported in a wide range of tumors (cholangiocarcinoma, breast cancer, prostate cancer, NSCLC, gastric adenocarcinoma, colorectal adenocarcinoma, carcinoma of unknown primary, and glioblastoma) with a variety of partners, including TACC3, PPAPDC1A, AFF3, SLC45A3 and AHCYL1, C10orf68, JAKMIP1, KIAA1598, NCALD, NOL4, NTM, PPAPDCA, TNIP2, and WHSC1 [12, 13, 117, 119, 123].